Objective. While rheumatoid arthritis (RA) is considered a prototypical autoimmune disease, the specific roles of B-cells in RA pathogenesis is not fully delineated. Methods. We performed microarray expression profiling of peripheral blood B-cells from RA patients and controls. Data were analysed using differential gene expression analysis and 'gene networking' analysis (characterizing clusters of functionally inter-relelated genes) to identify both regulatory genes and the pathways in which they participate. Results were confirmed by quantitative real-time polymerase chain reaction and by measuring the levels of 10 serum cytokines involved in the pathways identified. Results. Genes regulating and effecting the cell-cycle, proliferation, apoptosis, autoimmunity, cytokine networks, angiogenesis and neuro-immune regulation were differentially expressed in RA B-cells. Moreover, the serum levels of several soluble factors that modulate these pathways, including IL-1b, IL-5, IL-6, IL-10, IL-12p40, IL-17 and VEGF were significantly increased in this cohort of RA patients. Conclusions. These results outline aspects of the multifaceted role B-cells play in RA pathogenesis in which immune dysregulation in RA modulates B-cell biology and thereby contributes to the induction and perpetuation of a pathogenic humoral immune response.
Introduction
Rheumatoid arthritis (RA) is characterized by chronic inflammation involving connective tissues throughout the body, but particularly diarthrodial joints [1] . In a majority of patients with an active disease, circulating activated B-cells secrete rheumatoid factor (RF) in vitro [2, 3] , the levels of which correlate with the degree of clinical inflammatory activity and the likelihood of a severe and erosive disease course [4] . Moreover, a significant proportion of patients also have raised levels of antibodies to cyclic citrullinated peptides (anti-CCP) [5] and to proteins such as the immunoglobulin heavy-chain binding protein (anti-BiP) [6] , suggesting that the dysregulation of humoral immunity plays a significant role in RA.
Recently, the depletion of RA B-cells with targeted anti-B-cell therapy (rituximab) had profound disease-ameliorating effects, providing the first direct evidence that B-cells influence disease activity in RA [7] . Following B-lymphocyte depletion, a positive clinical response occurred in correlation with a significant drop in the levels of C-reactive protein (CRP) and auto-antibodies [IgA-, IgM-and IgG-class RFs, and anti-CCP]. These data suggest that B-cell dysregulation plays a significant role in RA pathogenesis that influences disease activity, prognosis and therapeutic response.
B-cells therefore mediate RA pathogenesis, which in turn affects B-cell biology, a complex interplay that can obscure our understanding of the relevance of a given B-cell process in RA. A small fraction of the total B-cell pool is found in the peripheral circulation and diminished numbers of circulating CD19þ B-cells are observed in RA patients-the likely result of increased trafficking and accumulation of activated and autoreactive B-cells in the synovial membrane of affected joints [8] . Since circulating B-lymphocytes are the source of synovial B-cells, it is informative to analyse the circulating counterparts of the locally accumulated autoreactive B-cells. Activated peripheral B-cells with autoreactive characteristics are typical in RA [8] , and as such are a ready source for identification of disease-specific changes in B-cell gene-expression. Moreover, circulating B-cells have proven to be a useful source for identifying mechanistic anomalies in auto-immune diseases including RA [8] [9] [10] [11] [12] .
Microarrays provide a powerful means of cataloguing genes that are affected by or are mediating a given disease. Increasingly informative softwares that aid in translating catalogues of genes from microarray experiments into an understanding of pathology are available. Biological systems are both redundant and highly networked. As a consequence, many functionally interrelated genes tend to be affected when consequences of pathology on a given pathway are significant. These pathways can then be characterized through secondary analysis of differentially regulated gene sets using clustering and networking algorithms, as well as visual analysis of gene function.
Herein, we utilized genome-scale microarrays with robust bioinformatics tools to create a catalogue of genes that are dysregulated in peripheral blood B-cells from RA patients relative to controls. To assess the relevance of these results, serum levels of 10 cytokines known to modulate a subset of the pathways identified were assessed. This combined-screening approach identified B-cell genes and B-cell growth, development and activation pathways affected in RA patients, and the potential disease modulators derived from these dysregulated cells.
Patients and methods

Patients and controls
The study population consisted of 10 adult patients (four males and six females; mean age 42 yr, range 22-67; mean duration of disease 1.6 yr, range 0.5-7) with active RA who fulfilled the American College of Rheumatology criteria [13] . All patients were referred from the Arthritis Department of the McBride Clinic and from primary physicians within the Oklahoma City Metropolitan Area. All patients were disease-modifying anti-rheumatic drug (DMARD) naı¨ve at enrolment, and stable doses of non-steroidal anti-inflammatory drugs (NSAIDs) and/or prednisolone ( 10 mg daily) were allowed. The Health Assessment Questionnaire (HAQ) and the Disease Activity Score (DAS28) [14] were assessed for all patients. Two patients from the original cohort were excluded from microarray analysis due to the low integrity of the separated RNA [cohort of patients for microarrays now being (n ¼ 8) three males and five females (mean age 38.25 yr, range 22-67; mean duration of disease 1.7 yr, range 0.5-7)]. Clinical and laboratorial characteristics of the patients included in the study are summarized in Table 1 . The cohort studied also included normal age-and sex-matched healthy controls (n ¼ 10, of which two were excluded from microarray analysis to match with the microarray patient cohort). The institutional review board at each study site approved the protocol, and all patients gave written informed consent according to the declaration of Helsinki.
RNA and sera preparation
Blood was collected in endotoxin-free silicone-coated tubes, both with and without additive. Sera were prepared as described [15] . B-cells were isolated by negative selection using a B-cell Negative Isolation Kit according to the manufacturer's instructions (Dynal Biotech Inc., Lake Success, NY, USA). To assess purity, B-cell preparations were stained with a monoclonal mouse, anti-human, anti-CD19-FITC-conjugated antibody (Sigma-Aldrich, St Louis, MO, USA), and the percent of CD19-positive cells was assessed by flow cytometry (FACSCalibur, Becton-Dickinson, San Jose, CA, USA). The purity of B-cells was over 95% for all samples. RNA was isolated from B-cells using a hybrid protocol that utilizes two common commercial RNA preparation reagents as previously described [16] . Separate pools of RNA from patients with RA or controls were formed by combining a total mass of 2 g total RNA within each group as previously described by Lawrance et al. [17] .
Preparation of cDNA for microarray hybridization
An Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) was used to measure RNA concentration and integrity as specified by the manufacturer. Integrity of the samples was determined using 28:18 S rRNA ratios with threshold ratio of 1.1 to insure that the RNA integrity adequate for analysis. Samples with significantly lower ratios typically exhibit degradation that affects the gene-expression levels in a non-uniform manner. A representative electropherogram of total RNA from one patient and one control are shown in Fig. 1 . Flourescently labelled cDNA was synthesized and purified as previously described [15] .
Microarrays
A commercially available genome-scale oligonucleotide library containing gene-specific 70 mer oligonucleotides representing 21 329 human genes was used for microarray production. The set includes 16 replicate spots of 12 random negative controls that have no significant homology to known human DNA sequences (Qiagen Inc., Valencia, CA, USA). Oligonucleotides were spotted onto Corning Õ UltraGAPS TM amino-silane coated slides, which were then rehydrated with water vapour, snap dried at 908C. Oligonucleotide DNAs were covalently fixed to the surface of the glass using 300 mJ of ultraviolet radiation at a 254 nm wavelength. Unbound, free amines on the glass surface were blocked for 15 min with moderate agitation in a solution of 143 mM succinic anhydride dissolved in 1-methyl-2-pyrolidinone, 20 mM sodium borate, pH 8.0. Slides were rinsed for 2 min in distilled water, immersed for 1 min in 95% ethanol and dried with a stream of nitrogen gas.
Hybridization was performed in an automated liquid delivery, air-vortexed, hybridization station for 9 h at 588C under an oilbased cover slip (Ventana Medical Systems Inc., Tucson, AZ, USA). Microarrays were washed at a final stringency of 0.1X SSC. Microarrays were scanned using a simultaneous dual-colour, 48-slide scanner (Agilent Technologies). Fluorescent intensity was quantified using Imagene TM software (BioDiscovery, Marina del Rey, CA, USA). ANA, antinuclear antibodies; CRP, C-reactive protein (normal 0.0-0.33 mg/dl); DAS, disease activity score; ESR, erythrocyte sedimentation rate (normal 0-20 mm/h); HAQ, health assessment questionnaire; HgB, haemoglobin (normal 116-171 g/l); RF, rheumatoid factor; WBC, white blood cell count (normal 3.7-11.6 Â 10 9 /l). *Indicates cohort used for microarrays.
Quantitative real-time PCR (qRT-PCR)
Gene-specific PCR primers were identified for each gene using 'Primer Express' software (Applied Biosystems Inc., Foster City, CA, USA) and the primers commercially prepared (Qiagen Inc.). Reverse-transcription reactions were run using 2 mg of pooled total RNA from patients or from controls. An external standard was added to each sample prior to cDNA synthesis, and the resultant levels of the PCR product were used for normalization of gene-expression concentrations. This consisted of 0.1 ng of Arabidopsis thaliana (RCA) mRNA (Stratagene, La Jolla, CA, USA). Synthesis of cDNA was done using the reverse transcriptase Omniscript RT TM according to the manufacturer's instructions (Qiagen Inc.). Small molecules and enzymes were removed from the reaction and a buffer exchange was carried out using the Montage PCR 96-well size exclusion filter system (Millipore, Billerica, MA, USA). For qRT-PCR, 2 l of this cDNA reaction was then added to a pre-made reaction mixture that contained the following components: 7.5 l of a standard commercial premixed PCR reagent solution (Syber Green 2Â PCR Master Mix, Applied Biosystems), 0.6 l of a solution containing 30 pmoles of genespecific forward and reverse primers, 30 pmoles of primers specific for the internal standard, and 4.9 ml of water. Reactions were denatured at 958C for 10 min and then PCR was carried out on an ABI PRISM 7700 thermocycler (Applied Biosystems) using the following cycling conditions for 40 cycles: 958C for 15 s and 608C for 1 min. A control reaction that did not contain human RNA ('no template control') was also run for each primer set to determine the extent, if any, of non-specific amplification occurring in a given reaction. All reactions were run in triplicate and average values reported.
Simultaneous cytokine quantitation with a suspension array system
Serum levels of 10 serum proteins, including interleukin (IL)-1, IL-5, IL-6, IL-10, IL-12p40, IL-17, vascular endothelial growth factor (VEGF), Tumor Necrosis Factor (TNF-) and Interferon (IFN-), selected on the basis of the related genomics data were measured using a bead-based immunoflourescence assay (Luminex Inc., Austin, TX, USA) as previously described [18, 19] .
Statistical analysis
Normalization was done using a robust two-step procedure as described [15, [20] [21] [22] . We employed a stringent cutoff, 10 S.D. above the mean of the random negative controls and a ratio in excess of three, to minimize the number of false positive results. From previous work [22] , we demonstrated that microarray noise is well characterized, therefore Gaussian expectation can be used to estimate inter-array variability. Inter-patient variability tends to be higher than inter-array variability (3 vs 9% CV). Capitalizing on this knowledge allows us to run a pair of pooled chips and accurately estimate the number of false positive results. The probability of selecting a false positive in this experimental dataset using the stringent cutoffs described above is P<9.35 E-06. The calculated family-wise error rate (FWER) based on this probability is very low, there is only a 19.6% chance of selecting one false positive in this analysis [23, 24] . An independent verification by qRT-PCR was also performed to assess the validity of the microarray results (see aforesaid). For the biometric multiplex assay, statistical differences in measured values were analysed using a Mann-Whitney U-test (P<0.05).
Results
Microarray gene-expression profiles of peripheral B-cells from RA patients vs controls
RNA from B-cells of eight RA patients and eight unaffected healthy individuals was pooled, labelled and hybridized to genome-scale microarrays containing probes for 21 329 genes. Data were normalized, and differentially expressed genes were identified [15, [20] [21] [22] . In hybridization-based expression profiling, false positive selections can arise due to cross-hybridization, which results in misidentification of a given differentially expressed signal. The potential for cross-hybridization is inversely proportional to the signal level. Oligonucleotides with no significant homology to characterized human DNA sequences were included in the array to provide an internal standard for non-specific hybridization such that a selection threshold for minimizing crosshybridization signals could be established. To insure the fidelity of selections, a stringent expression threshold was used to identify likely true positives. Only genes with signal intensities greater than 10 S.D. above the mean of the distribution of random negative controls, and induced or repressed 3-fold or greater in RA vs controls, were catalogued and used for further analysis. Using these selection criteria, 305 genes were identified as over-expressed in RA B-cells, and 231 genes were repressed, i.e. more highly expressed in control B-cells (Fig. 2) . The online supplemental table summarizes expression levels for all differentially identified genes (http://microarray.omrf.org/szodoray/array.xls). The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), and are accessible through GEO Series accession number GSE4255.
Functional clustering of differentially expressed genes
The most significant phenotypical changes will be the most likely to be represented by a group of differentially expressed and functionally related genes. As such, the inherent redundancies of biological systems facilitate the elucidation of pathways of likely pathological significance through the functional clustering of genes identified as differentially expressed.
Functionally associated networks of the differentially expressed genes were constructed using Pathway Assist software (Stratagene Inc.). This software uses the KEGG, DIP and BIND databases and natural language scans of Medline to identify functional associations among differentially expressed genes and represents these associations graphically as a network. A significant proportion of the genes with defined biological function could be associated with mechanisms of relevance to the normal and pathological function of B-cells defined as five functional classes that include: cell activation, proliferation and apoptosis (31 genes); autoimmunity (five genes); cytokines, cytokinereceptors and cytokine-mediated processes (eight genes); neuroimmune regulation (two genes); and angiogenesis (five genes) ( Table 2 , Fig. 3A-C) .
Confirmation of differential expression by qRT-PCR
The initial validation of the microarray results was done by re-evaluating the relative expression of 13 genes found to be up-regulated in RA B-cells with qRT-PCR. Genes from each of the five functional classes were randomly chosen for re-analysis including: CNNM4, BARD1, U5-116KD, TLR9, IL-5RA, IL-10, IL-12A, PTX3, CRLF1, CHRNB1, DRD2, MMP28 and VEGFC. Consistent with the microarray results, these genes were also found to be up-regulated in RA B-cells by RT-PCR, albeit minimally for one of the 13: IL-5RA (Fig. 4) .
Multiplex profiling of soluble inflammatory mediators in RA patients' sera
Functional pathway analysis revealed that many of the genes modulated in RA B-cells are associated with cytokines and growth factors likely to influence B-cell biology (Fig. 3A-C) . To assess if these soluble mediator-driven pathways may be of relevance to RA pathology and to further test the validity the microarray results, serum concentrations of nine B-cell-modulating cytokines and one growth factor identified by pathway analysis were measured in 10 RA patients and 10 unaffected individuals. Cytokines included in this analysis were chosen based on observed up-regulation of the gene encoding the cytokine or a subunit of the cytokine in RA patients. Also chosen were cytokines directly or indirectly associated, with disease-relevant pathways identified in the above analysis which suggested that a given cytokine-modulated pathway was disrupted in RA B-cell biology.
The average serum levels of seven cytokines and VEGF were significantly higher in patients including: IL-1 (RA: mean 275±79.44 pg/ml vs control: mean 12±0.55 pg/ml, P ¼ 0.023); IL-5 (RA: mean 146.6±62.34 pg/ml vs control: mean 5.95±2.84 pg/ml, P<0.0001); IL-6 (RA: mean 306±123.9 pg/ml vs control: mean 6.55±1.78 pg/ml, P ¼ 0. 
Genes involved in B-cell activation, cell-cycle progression, proliferation and apoptosis inhibition NM_005980 S100P S100 calcium-binding protein P Contains EF-hand calcium-binding motifs and stimulates cell proliferation and survival in various cell-types [46, 47] . NM_002964 S100A8 S100 calcium-binding protein A8 (calgranulin A) Regulates cell cycle progression, differentiation, and cell activation. Expressed and secreted by LPS-activated B-cells in mice [48] . NM_002965 S100A9 S100 calcium binding protein A9 (calgranulin B) NM_000858 GUK1 Guanylate kinase 1 Antigen receptor signalling molecule. In murine models GUK1 modulates B-and T-cell activation and proliferation [49, 50] . NM_00209 GSPT1 G1 to S phase transition Regulates G1 to S phase-transition in mammalian cells [51] . NM_020184 CNNM4* Cyclin M4 Regulator of cell-cycle progression in various cell-types [52] . NM_007111 TFDP1 Transcription factor Dp-1 A G1 cell-cycle-related protein that forms heterodimers with E2F, regulates expression of genes important for G1 to S progression [53] . May promote cell-cycle progression in human B-cell neoplasms [54] . NM_000791 DHFR Dihydrofolate reductase Activity of DHFR promoter increases at the G1-S-phase boundary of the murine cell cycle [55] Modulates cell development, activation, growth and motility in human cell-lines [64] . NM_003371 VAV2 Homo sapiens vav 2 oncogene Vav family required for B-cell development and function. These proteins modulate BCR-induced changes in the cell cycle, differentiation, Ig production and apoptosis in eukaryotic cells [65] . NM_005235 ERBB4 v-erb-a erythroblastic leukaemia viral oncogene homolog 4 A transmembrane receptor tyrosine kinase that regulates cell proliferation and differentiation in mammalian cells. Overexpression and mutation are implicated in neoplastic transformation [66, 67] . NM_015313 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 Expression is induced following CD40 stimulation. Overexpression of GEF mimics some effects of CD40 stimulation, including changes in B-cell structure, NF-kappaB activation and apoptosis inhibition in murine cell-lines [68] .
G-protein-coupled receptor for Sphingosine-1-phosphate, which stimulates cell growth, prevents apoptosis, modulates actin cytoskeleton and cell shape, migration and invasion in animal models [69] . NM_002837 PTPRB Protein tyrosine phosphatase, receptor type, B Member of the protein tyrosine phosphatase (PTP) family, which play critical roles in lymphoid biology [70] . NM_000835 GRIN2C Glutamate receptor, ionotropic, N-methyl-D-aspartate 2C Modulates human lymphocyte activation [71] . NM_006262 PRPH Peripherin Mediates signal transduction events that play a role in the regulation of cell development, activation, growth and motility in humans [72] . NM_006890 CEACAM7 Carcinoembryonic antigen-related cell adhesion molecule 7 Controls cell proliferation. The plasma CEA level of patients with seropositive RA is higher than that of normal and control subjects [73] . BC017722
Ephrin-A3 Ephrin-A3 Ephrins may play a role in the interaction between human activated B-lymphocytes and dendritic cells [74] . NM_005915 MCM6 MCM6 minichromosome maintenance deficient 6 (MIS5 homolog, Schizosaccharomyces pombe) (Saccharomyces cerevisiae)
Essential for the initiation of eukaryotic genome replication [75] .
(Continued)
Genome-scale assessment of peripheral blood B-cell molecular homeostasis [86] .
Cytokines, cytokine-receptors and genes related to cytokine-mediated processes NM_002852 PTX3* Pentaxin-related gene Induced by IL-1 in human cell-lines [87] . NM_000564 IL5RA* IL-5 receptor, alpha Human B-cells express IL-5 receptor messenger ribonucleic acid and respond to IL-5 with enhanced IgM production [88] . NM_000572 IL10* IL-10 Sustains B-cell viability, promotes differentiation and antibody secretion, and inhibits apoptosis, also involved in the HPA axis regulation in humans [89, 90] . X68994 CREB CREB gene, exon Y CREB-1 binds to CRE1 and CRE4 in the upstream enhancer of the IL-10 promoter [91] . NM_000882 IL12A* IL-12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) IL-12 is secreted mainly by B-cells-and augments antigen-dependent proliferation of activated human T-lymphocytes [44] . AF208111 EVI27 Truncated IL-17 receptor homologue precursor Expressed in B-cell, T-cell and myeloid cell lines. Evi27 expression is tightly regulated during haematopoietic differentiation in humans [37] . NM_004750 CRLF1* Cytokine receptor-like factor 1 Expression of CRLF1 is induced by TNF-, IL6, and IFN-in mice and humans [92] .
Genes related to neuro-immune regulation NM_000747 CHRNB1* Cholinergic receptor, nicotinic, beta polypeptide 1 Beta subunit of the muscle nicotinic acetylcholine receptor in mice [29] . NM_000795 DRD2* Dopamine receptor D2, transcript variant 1 Prevously found to be expressed on human B-cells [31] . Serum dopamine elevated in RA [32] .
Genes related to angiogenesis NM_014237 ADAM18 A disintegrin and metalloproteinase domain 18 Potential role in cartilage destruction [93] and angiogenesis in human cells [94] . NM_000800 FGF1 Fibroblast growth factor 1 (acidic), transcript variant 1 Mitogen, cell survival activity, pro-angiogenic factor in human cells [95, 96] . NM_004101 F2RL2 Coagulation factor II (thrombin) receptor-like 2 Thrombin receptor that mediates phosphoinositide hydrolysis. Thrombin increases VEGF secretion and enhances matrix metalloprotease expression in human cells [97] . NM_032950 MMP28* Matrix metalloproteinase 28 Angiogenic factor in human cartilage [98] . NM_005429 VEGFC* VEGF C Key mediator of angiogenesis. Found in the synovial fluid and serum RA patients [99, 100] .
*Genes verified by qRT-PCR.
VEGF (RA: mean 120.2±29.83 pg/ml vs control: mean 43.2±17.29 pg/ml, P ¼ 0.028).
The serum levels of TNF-(RA: mean 55.81±34.08 pg/ml vs control: mean 29.02±15.82 pg/ml, P ¼ 0.57) and IFN-(RA: mean 17.72±11.6 pg/ml vs control: mean 4.89±0.85 pg/ml, P ¼ 0.52) were non-significantly elevated in RA patients compared with healthy controls (Fig. 5) .
Discussion
In order to identify genes and pathways of significance to the pathological state of RA B-cells, gene expression profiles from genome-scale microarrays were compared between peripheral B-cells of RA patients and unaffected controls. A large set of genes with diverse functions were differentially expressed, suggesting that the dysregulation of B-cell biology in the RA patients within this cohort is multifaceted. Many clinically relevant regulatory processes in RA are highly coordinated. We utilized this principle to highlight likely regulators and effectors of disease pathology within the list of differentially regulated genes using software that identifies sets of genes that are members of established functional networks.
Our general interpretation of the data is that the gene-expression pattern of these B-cells both reflects a response to exogenous, pro-inflammatory mediators (e.g. cytokines), also endogenous gene-regulatory defects.
Functional clustering of genes from RA B-cells revealed complex networks of inflammatory mediators and pathways that likely influence disease pathology. These networks were categorized into five broad-based groups including: cell activation, proliferation and apoptosis; autoimmunity; neuro-immune regulation; angiogenesis; and cytokines, cytokine receptors and cytokine-mediated processes.
The largest functional group contains genes modulating B-cell activation, cell-cycle progression, proliferation and apoptosis, suggesting that RA B-cells are hyperproliferative and activated in response to disease pathology. In germinal centres, B-cells are rescued from cell death by antigen-binding; however, self-reactive B-cells undergo negative selection, which results in deletion by apoptosis or anergy. Herein, several apoptosis-inhibitory genes were overexpressed, suggesting that these RA B-cells bypass negative selection during auto-antigen encounter and escape from deletion. These results support the hypothesis that autoreactive B-cells survive in RA due to disease-specific defects in pathways controlling proliferation, activation and apoptosis. This hypothesis is further supported by the fact that the genes identified are modulated by soluble factors known to support B-cell proliferation, survival and activation, including IL-1, IL-5, IL-6 and IL-10, and that these factors are themselves highly up-regulated in RA patients' sera.
Genes, associated with autoimmunity comprise a second functional cluster. Particularly notable in this cluster is the Toll-like receptor 9 (TLR9), transcript variant A, which is overexpressed in RA B-cells. In humans, the expression of TLR9 appears to be relatively restricted to B-cells and CD123þ dendritic cells where it functions as a modulator of bacterial DNA recognition. Upon the detection of CpG motifs on bacterial DNA, B-cells are induced to proliferate, secrete immunoglobulins, up-regulate costimulatory molecules and have enhanced abilities to induce Th1 cell responses. Bacterial DNA costimulates murine B-cell activation through cell-membrane immunoglobulins, thereby promoting the development of antigen-specific responses [25] . Microbial pathogen-associated molecular patterns (PAMPs) engage and/or up-regulate TLR expression, and thus create a synergy with autoantibody-autoantigen immune complexes in mice [26, 27] . The importance of TLR9 activation in systemic lupus erythematosus pathophysiology was recently demonstrated in studies showing that DNA-containing immune complexes traffic to intracellular compartments, wherein they initiate TLR9 activation and a resulting production of proinflammatory cytokines [26] .
TLR9-signalling thus provides an intriguing potential mechanistic link between the association of infection and disease flares in RA [27] . The fact that the TLR9 gene is up-regulated on average in RA B-cells suggests that it may also be of central importance in the initiation and perpetuation of autoimmunity and inflammation in RA in an infection-independent manner.
A third functional grouping was composed of neuro-immune modulators. This included the gene encoding the cholinergic receptor, nicotinic, -polypeptide 1 (CHRNB1). Acetylcholine (ACh) is well known as a neurotransmitter in both the central and peripheral nervous systems in mammalian species characteristically identified as a modulator of several classical immune reactions via the vagus nerve. Extensive parasympathetic and sympathetic inputs modulate immune activity through the ACh and adrenergic receptors. Both muscarinic and nicotinic ACh-receptors have been identified in murine lymphocytes and their stimulation by muscarinic and nicotinic agonists elicits a variety of functional and biochemical effects [28] . Recent findings support the idea that immunological stimulation leads to AChreceptor gene expression in lymphocytes in animal models. Stimulation of nicotinic ACh-receptors with ACh or nicotine causes rapid and transient Ca 2þ signalling and activation in B-cells [29] . On the basis of these findings, it has been postulated that the parasympathetic nervous system may play a role in immune-neurohumoral crosstalk. A second neurotransmitter-receptor-gene overexpressed in RA B-cells was the dopamine receptor D2 (DRD2), transcript variant 1. Previously, it has been described that human B-cells have a consistent expression of D2 receptors [30] . Moreover, the serum levels of dopamine are higher in the RA subjects than in the control subjects, suggesting that neuro-immune regulation is altered in RA [31] . Our findings underscore the importance of communication between peripheral B-lymphocytes and the sympathetic and parasympathetic system, the imbalance of which may contribute to the activation of circulating B-lymphocytes and the development of humoral autoimmune processes in RA.
A fourth grouping is composed of genes related to angiogenesis, including the pro-angiogenic factors VEGFC, FGF1 and F2RF2. Angiogenesis is central to the development and perpetuation of rheumatoid synovitis. New blood vessel formation in the synovium occurs early in RA and likely fuels pannus development [32] [33] [34] .
Not surprisingly, cytokine and cytokine-receptor genes are also differentially expressed in RA B-cells. The receptor genes include IL-5 receptor-alpha (IL5RA) and an IL-5-specific subunit of the heterodimeric IL-5 receptor. IL-5 induces B-cell proliferation [35] . Within this cohort, serum IL-5 levels were increased in the RA patients 24-fold on average. The fact that the IL-5-receptor gene is up-regulated in RA B-cells and IL-5 is up-regulated in RA sera imply that this cytokine plays a role in the dysregulation of B-cell biology in RA. Interestingly, human B-cells express message for IL-5R but can respond to IL-5 only if appropriately stimulated to undergo terminal differentiation, suggesting that if IL-5 affects RA B-cells, it functions by modulating a B-cell pool that is in a higher state of activation on average than B-cells from healthy controls.
The receptor for IL-17 family member IL-17E [36] , the IL-17 receptor homologue precursor (EVI27), was also up-regulated in RA B-cells. IL-17 is expressed in RA synovium where it contributes to inflammation, angiogenesis, tissue remodelling, and joint errosions directly and through induction of other proinflammatory cytokines [37] [38] [39] . Consistent with previous results, which suggest that IL-17 plays a significant role in RA, serum levels of IL-17 were found to be highly increased in this RA cohort.
The cytokine-gene transcripts encoding IL-10 and IL-12A (IL-12p35) were also up-regulated in RA B-cells. Similarly, serum levels of IL-10 and IL-12 are up-regulated in the RA patients within this cohort. IL-10 plays a complex and varied role in B-cell biology including modulating cell viability and differentiation, enhancing the expression of MHC class II antigens and immunoglobulins, and inhibition of apoptosis of germinal-centre B-cells. In activated T-cells, IL-12 augments antigen-dependent proliferation [40, 41] , providing a potential positive feedback during cognate T-B interactions, which may contribute to the chronicity of immune dysregulation in RA.
Interestingly, a clear role for Th1 immunity has also been demonstrated, with recent evidence including characterization of disease-promoting Th1 CD4þ memory cells in RA synovium and dysregulation of Th2 and CD25þ regulatory T-cells in RA patients, which is thought to predispose patients to peripheral tolerance breakdown and subsequent pathological Th1-mediated immune responses, albeit in a Th2-dependent manner [42, 43] .
The simultaneous secretion of IL-10 and IL-12 by B-cells (e.g. effector B-subsets, such as Be2-cells) has been previously described [44] . Our studies demonstrated that on average the RA B-cells derived from the patients in this cohort have higher IL-10 and IL-12p35 transcripts when compared with healthy controls, suggesting that B-cells are not strictly polarized in RA, but contribute to immunopathogenesis in a complex manner.
In conclusion, these studies suggest that the effects of RA on B-cells and the effects of B-cells on RA are pleotropic. Genes and cytokines regulating key aspects of B-cell immunology including growth, differentiation, apoptosis and activation are differentially expressed and likely dysregulated in RA B-cells. These results support the growing evidence most directly demonstrated in clinical trials of B-cell depletion therapy, that B-cells contribute to disease pathology in RA [45] . The results presented herein highlight multiple key pathophysiological processes of the disease likely affected by the B-cell-depletion agents and may aid in guiding future applications of this therapy as well as the development of novel therapies targeting the genes and pathways highlighted in this study.
